Orphan drug biotech Retrophin is the new owner of an FDA-approved rare disease treatment and a potentially lucrative voucher for a future speedy review thanks to a $75 million buyout agreement.
As Endo showed last week with its failed $10 billion bid for North Carolina's Salix, it's willing to shell out some serious dough if the right target comes along. The question is, what's left?
Kite Pharma, a leader among companies in the fast-moving field of cancer immunotherapy, is expanding its arsenal of potential treatments and making European landfall with a biotech buyout.
Actavis and Allergan can finally celebrate: They've cleared the last hurdle to closing their $66 billion merger agreement.
Pfizer CEO Ian Read got a nice pay bump for 2015, with a total package of $23.3 million--more than one-quarter bigger than the previous year's total. But a big chunk of that increase came in the value of his pension. Back that out, and Read's compensation only grew by $280,000.
Heard the Teva-Mylan takeover rumors? Forget them, one analyst says.
Respiratory biotech Pulmatrix is taking an end-around path to the public market, signing a deal to merge with tiny Ruthigen to better fund its pipeline of inhalable treatments.
So you thought you could wrestle Salix away from Valeant, Endo? The Canadian pharma has a message for you: Think again.
Pershing Square Capital Management recently took a 5% stake in Valeant Pharmaceuticals in what some Wall Street insiders say is the opening salvo in what could be an eventual merger between Valeant and animal health giant Zoetis.
Ember Therapeutics, a Third Rock Ventures-founded biotech startup that closed its doors late last year, is getting a second chance thanks to a small New York drug developer.